ASX:SGZ (SGZ.AX) (SGZ) Stock Price, News & Analysis → Strange new buyer driving up gold (From Stansberry Research) (Ad) Free SGZ Stock Alerts Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (SGZ.AX) alerts: Email Address Ad Behind the MarketsTiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> About (SGZ.AX)Scotgold Resources Limited is engaged in the advancement of the Cononish Gold and Silver Project in Scotland's Grampian Highlands to a production decision. The Company is engaged in the exploration of the tenements comprising the Grampian Gold Project with the view of identifying further project opportunities. The Grampian Gold Project comprises Crown Option agreements covering approximately 4,100 square kilometers in the south west Grampians of Scotland and covers some areas of the Dalradian geological sequence in the United Kingdom. The Dalradian sequence extends to the southwest from Scotland into Northern Ireland. It holds approximately five mines located in the United Kingdom, including Glen Orchy, Glen Lyon, Inverliever, Knapdale and Ochils. Its Pomar license area covers approximately 260 square kilometers in eastern central Portugal, near Castelo Branco and includes the antimony mines of das Gatas, Pomar and Casalinho, in addition to numerous small scale trials and occurrences.Read More Ad Behind the MarketsTiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> SGZ Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive SGZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (SGZ.AX) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/29/2017Today4/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorN/A Industry N/A Sub-IndustryN/A Current SymbolASX:SGZ CUSIPN/A CIKN/A Webwww.scotgoldresources.com.au Phone+61-8-94633260FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDavid SwanChief Financial OfficerRichard Quentin Gray (Age 56)Managing Director, Executive Director Richard BarkerCompany Secretary, DirectorGabriel ChiappiniCompany Secretary, DirectorChristopher John Stuart Sangster (Age 58)Non-Executive Director Phillip Sidney Raymond JacksonNon-Executive Independent DirectorMore Executives SGZ Stock Analysis - Frequently Asked Questions How were (SGZ.AX)'s earnings last quarter? (SGZ.AX) (ASX:SGZ) posted its quarterly earnings results on Friday, September, 29th. The company reported $0.00 earnings per share for the quarter. This page (ASX:SGZ) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchThe #1 Crypto for 2024InvestorPlaceYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (SGZ.AX) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.